Back to Search
Start Over
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals
- Source :
- Journal of the College of Physicians and Surgeons Pakistan. 30:124-128
- Publication Year :
- 2020
- Publisher :
- College of Physicians and Surgeons Pakistan, 2020.
-
Abstract
- Chloroquine (CQ) and its derivatives such as hydroxychloroquine (HCQ) remain mainstay of therapy for malaria. These drugs are also approved for certain autoimmune diseases including systemic lupus erythematosus. The antiviral activities of these drugs and their mechanisms have been studied in vitro previously against various viruses including severe acute respiratory syndrome coronavirus (SARS-CoV). During the current coronavirus disease 2019 (COVID-19) pandemic, in vivo and in vitro investigations of these drugs have demonstrated potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The authors used the keywords to find the relevant studies, like COVID-19, SARS-CoV-2, pandemic, complications, repositioning, toxicity, overdose, treatment plan, implication strategies, prevention, chloroquine, hydroxychloroquine, clinical trials, drug interactions, and practices advice, etc., in Pubmed and Google Scholar. This review aims to provide a detailed insight of practice implications related to these drugs, which would aid healthcare professionals to ensure the safe use of these drugs during the management of patients with COVID-19 disease. Key Words: Chloroquine, Hydroxychloroquine, COVID-19, SARS-CoV-2, Practice implications.
- Subjects :
- Drug
medicine.medical_specialty
viruses
media_common.quotation_subject
Pneumonia, Viral
0211 other engineering and technologies
02 engineering and technology
Disease
Antiviral Agents
Betacoronavirus
03 medical and health sciences
0302 clinical medicine
Chloroquine
Pandemic
Humans
Medicine
030212 general & internal medicine
Intensive care medicine
Pandemics
media_common
021110 strategic, defence & security studies
SARS-CoV-2
business.industry
COVID-19
Hydroxychloroquine
General Medicine
medicine.disease
COVID-19 Drug Treatment
Clinical trial
Pneumonia
Coronavirus Infections
business
Malaria
medicine.drug
Subjects
Details
- ISSN :
- 16817168 and 1022386X
- Volume :
- 30
- Database :
- OpenAIRE
- Journal :
- Journal of the College of Physicians and Surgeons Pakistan
- Accession number :
- edsair.doi.dedup.....1972f39823d6e88a2149a585ef371e6c
- Full Text :
- https://doi.org/10.29271/jcpsp.2020.supp2.124